BTIG Reiterates Buy on ArriVent BioPharma, Maintains $29 Price Target

Benzinga · 1d ago
BTIG analyst Jeet Mukherjee reiterates ArriVent BioPharma (NASDAQ:AVBP) with a Buy and maintains $29 price target.